Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

Mise à jour : Il y a 4 ans
Référence : NCT00326339

Femme et Homme

Extrait

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, ascending dose, dose ranging study to evaluate up to three doses of R935788 (50 mg bid, 100 mg bid and 150 mg bid). Approximately 180 patients who have had rheumatoid arthritis for a minimum of 12 months and who have been receiving a weekly methotrexate (MTX) dose for a minimum of 6 months will be enrolled into the study.


Critère d'inclusion

  • Rheumatoid Arthritis

Liens